Diadema Partners’s Vir Biotechnology VIR Stock Holding History

Diadema Partners’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$796K	Sell	88,800 -400	-0.4%	-$3.19K	0.14%	92
2025 Q4	$538K	Buy	+89,200	New	+$531K	0.09%	114
2025 Q1	–	Sell	-100,000	Closed	-$734K	–	153
2024 Q4	$734K	Buy	+100,000	New	+$789K	0.31%	64

Other funds holding VIR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

GSK plc London $599M AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Diadema Partners's VIR Position: Q1 2026 in Review

Diadema Partners sold out of Vir Biotechnology (VIR) in Q1 2026, closing a stake of 100,000 shares — an estimated $797K sold.

Diadema Partners first reported a position in VIR in Q4 2025 and held it in 1 quarter. The position peaked at $603K in Q4 2025. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

Diadema Partners reported no remaining Vir Biotechnology position as of Q1 2026 after selling out during the quarter.
Diadema Partners sold 100,000 Vir Biotechnology shares in Q1 2026, an estimated $797K.
Diadema Partners first reported a position in Vir Biotechnology in Q4 2025 and held it in 1 quarter.
Diadema Partners's Vir Biotechnology position peaked at $603K in Q4 2025.
251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.